# Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Study · id `cardio:ct-nct02157298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02157298](<https://clinicaltrials.gov/study/NCT02157298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02157298

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

## Technical summary

Registry record NCT02157298. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-03-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 266 participants (enrolled count; ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Start date: 2014-06 (registry gives no type) (ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Completion: 2015-11 (actual) (ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Results first posted: 2016-03-17 (ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02157298, source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02157298-2016-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin 5 mg
- Intervention (Drug): Placebo tablet
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 31421cbcb4c3711eebfa8b3ab5e84a5dcc8630379c19c886e61a2dbd4588512a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
